Drugs / CD19 CAR-T Cell Therapy
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT07613788 Background | May 2026 → Nov 2028 expected | large B-cell lymphoma | Ruijin Hospital | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CD19 CAR-T Cell Therapy | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07613788 ↗ |
| Modality | Cell therapy | “Participants will receive CD19-directed CAR-T cell therapy after lymphodepleting chemotherapy.” NCT07613788 ↗ |
| Target | CD19 | “Participants will receive CD19-directed CAR-T cell therapy after lymphodepleting chemotherapy.” NCT07613788 ↗ |